Day One Biopharmaceuticals (DAWN) to Release Earnings on Wednesday

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) is set to post its quarterly earnings results after the market closes on Wednesday, October 30th. Analysts expect Day One Biopharmaceuticals to post earnings of ($0.22) per share for the quarter. Persons that are interested in registering for the company's earnings conference call can do so using this link.

Day One Biopharmaceuticals (NASDAQ:DAWN - Get Free Report) last announced its earnings results on Tuesday, July 30th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.75) by $0.70. The firm had revenue of $8.19 million during the quarter, compared to analyst estimates of $0.90 million. On average, analysts expect Day One Biopharmaceuticals to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Day One Biopharmaceuticals Stock Down 0.9 %

DAWN traded down $0.13 during trading on Wednesday, hitting $14.33. 938,726 shares of the stock were exchanged, compared to its average volume of 923,188. Day One Biopharmaceuticals has a 1-year low of $9.76 and a 1-year high of $18.07. The stock has a fifty day moving average price of $14.10 and a two-hundred day moving average price of $14.37. The firm has a market capitalization of $1.25 billion, a P/E ratio of -5.72 and a beta of -1.51.

Analysts Set New Price Targets

Several research firms recently commented on DAWN. Piper Sandler reiterated an "overweight" rating and issued a $40.00 price target on shares of Day One Biopharmaceuticals in a research report on Monday, July 8th. Needham & Company LLC upped their target price on shares of Day One Biopharmaceuticals from $32.00 to $33.00 and gave the company a "buy" rating in a report on Wednesday, October 9th. Bank of America upgraded shares of Day One Biopharmaceuticals from an "underperform" rating to a "buy" rating and increased their target price for the stock from $11.00 to $24.00 in a research note on Thursday, August 1st. JPMorgan Chase & Co. dropped their price target on Day One Biopharmaceuticals from $38.00 to $36.00 and set an "overweight" rating on the stock in a research report on Tuesday, August 6th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $40.00 price objective on shares of Day One Biopharmaceuticals in a research report on Thursday, August 1st. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $35.71.

Insider Transactions at Day One Biopharmaceuticals

In other news, CFO Charles N. York II sold 2,633 shares of the company's stock in a transaction on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $36,862.00. Following the transaction, the chief financial officer now directly owns 232,485 shares of the company's stock, valued at $3,254,790. This represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. In other news, CFO Charles N. York II sold 2,633 shares of Day One Biopharmaceuticals stock in a transaction that occurred on Friday, August 16th. The shares were sold at an average price of $14.00, for a total transaction of $36,862.00. Following the completion of the sale, the chief financial officer now directly owns 232,485 shares in the company, valued at approximately $3,254,790. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Samuel C. Blackman sold 2,232 shares of the company's stock in a transaction that occurred on Friday, August 16th. The stock was sold at an average price of $14.00, for a total value of $31,248.00. Following the completion of the sale, the insider now owns 1,127,535 shares in the company, valued at approximately $15,785,490. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 48,748 shares of company stock valued at $689,072. Corporate insiders own 8.40% of the company's stock.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.